Metabolic and Body Composition Research
Preclinical investigation of compounds studied for growth hormone axis modulation, lipolysis, insulin sensitivity, and body composition outcomes in rodent metabolic models.
Research Overview
Metabolic and body composition research examines peptide compounds that interact with growth hormone axis signaling, adipose tissue biology, and systemic metabolic regulation in preclinical rodent models. The primary research model systems include diet-induced obesity (DIO) C57BL/6 mice on high-fat diet protocols, ob/ob and db/db genetic obesity models, GH-deficient rodent models, aged murine cohorts with somatopause, and standard Sprague-Dawley rats in pharmacokinetic studies. Tesamorelin (a GHRH analog stabilized with a trans-3-hexenoic acid modification) was developed by Theratechnologies and has the most extensive published preclinical literature of any GHRH analog, with multiple rat and primate pharmacokinetic studies documenting GH pulse augmentation and downstream IGF-1 elevation. AOD-9604, a C-terminal GH fragment corresponding to residues 177 to 191, was developed by Metabolic Pharmaceuticals and was studied in DIO murine models for lipolytic activity independent of full GH receptor engagement. CJC-1295 (with DAC modification for extended half-life) combined with Ipamorelin (GHSR-1a selective ghrelin mimetic) has been characterized in Wistar rat GH pulse studies.
Key Research Findings
Findings from preclinical in vitro and in vivo model systems. All summaries reference published research models.
GH Pulse Augmentation by GHRH Analogs in Rat Studies
Tesamorelin pharmacodynamic studies in Sprague-Dawley rats documented dose-dependent increases in GH pulse amplitude and downstream IGF-1 levels, with treated animals showing 2 to 4-fold elevated GH peak concentrations compared to vehicle controls at comparable time points following subcutaneous administration. Primate pharmacokinetic studies in cynomolgus monkeys documented a longer effective half-life for Tesamorelin compared to native GHRH(1-44) due to its stabilizing N-terminal modification.
Lipolytic Activity of AOD-9604 in Diet-Induced Obesity Murine Models
Heffernan et al. and Metabolic Pharmaceuticals researchers documented that AOD-9604 (GH fragment 177-191) produced lipolytic effects in DIO C57BL/6 mice on high-fat diet, with treated animals showing reduced epididymal fat pad mass compared to vehicle controls at comparable time points, without the insulin-desensitizing effects associated with full-length GH administration. The lipolytic activity was proposed to involve a distinct receptor interaction from the canonical GH receptor.
Metabolic Flexibility Enhancement by MOTS-c in Murine Subjects
Lee et al. (Cell Metabolism, 2015) documented that MOTS-c administration improved glucose tolerance and insulin sensitivity in high-fat diet-fed C57BL/6 mice, with treated animals showing significantly lower blood glucose in oral glucose tolerance tests and insulin tolerance tests compared to vehicle-treated HFD controls at 8 weeks of treatment. The mechanism involved AMPK activation in skeletal muscle and enhanced GLUT4 translocation to the plasma membrane in muscle cells of treated animals.
Synergistic GH Secretion by Combined GHRH and Ghrelin Receptor Agonism
Combined administration of CJC-1295 and Ipamorelin in Wistar rat GH pulse studies documented synergistic GH secretory responses substantially greater than either compound alone, consistent with the distinct receptor mechanisms of GHRH receptor and GHSR-1a agonism acting on complementary pituitary somatotroph signaling pathways. Serial blood sampling studies showed that combined administration produced GH pulse amplitudes exceeding those achieved by either compound at double the individual dose.
Compounds Studied in This Area
Research compounds with documented preclinical activity in this domain.
Broader Research Context
Metabolic compound research in the peptide field has benefited from well-characterized rodent model systems for studying growth hormone axis biology and adipose metabolism. The Tesamorelin literature is notable for the extent of its pharmacological characterization, reflecting its development as a pharmaceutical compound. The AOD-9604 literature includes studies from multiple Australian and US research groups examining its lipolytic mechanism and metabolic safety profile in animal models. MOTS-c research has been primarily advanced by the Chang laboratory and collaborators, with the Cell Metabolism 2015 paper establishing the mitochondrial-derived peptide concept and its metabolic research applications.
Research Questions
Continue Your Research
Browse all research areas or explore the full Research Library for compound comparisons, study indexes, and use case guides.